(Q43672287)

English

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

scientific article published in June 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 November 2017

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection (English)

1 reference

Europe PubMed Central

25 November 2017

0 references

liver transplantation

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Rosenau J

1

1 reference

Europe PubMed Central

25 November 2017

Bahr MJ

2

1 reference

Europe PubMed Central

25 November 2017

Tillmann HL

3

1 reference

Europe PubMed Central

25 November 2017

Trautwein C

4

1 reference

Europe PubMed Central

25 November 2017

Klempnauer J

5

1 reference

Europe PubMed Central

25 November 2017

Manns MP

6

1 reference

Europe PubMed Central

25 November 2017

Böker KHW

7

1 reference

Europe PubMed Central

25 November 2017

publication date

1 June 2001

1 reference

Europe PubMed Central

25 November 2017

Journal of Hepatology

1 reference

Europe PubMed Central

25 November 2017

34

1 reference

Europe PubMed Central

25 November 2017

6

1 reference

Europe PubMed Central

25 November 2017

895-902

1 reference

Europe PubMed Central

25 November 2017

Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation in European patients with the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine for hepatitis B in liver transplantation: a single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibodies against the GB virus C envelope 2 protein before liver transplantation protect against GB virus C de novo infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B and C coinfections and persistent hepatitis B infections: clinical outcome and liver pathology after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulminant hepatitis B virus: recurrence after liver transplantation in two patients also infected with hepatitis delta virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Adefovir dipivoxil

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2801%2900089-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0168-8278(01)00089-7

1 reference

Europe PubMed Central

25 November 2017

1 reference

Europe PubMed Central

25 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43672287&oldid=2102418887"